OVERVIEW

The Congress on Cellular and Humoral Immunotherapy in Autoimmunity (CHIA 2025) is organized by CME Congresses Ltd and will be held from Sep 18 - 20, 2025 at The Star Meridian, Paris, Ile-de-France, France.

Description:
The field of immunotherapy is advancing rapidly, and this conference provides a vital platform for exploring the latest breakthroughs and emerging trends in both cellular and humoral immunotherapies, particularly in the context of autoimmune diseases. This year’s theme emphasizes bridging the gap between treatments for haematological malignancies and autoimmune disorders, highlighting the significant overlap and unique challenges shared by these fields.

Throughout the congress, we will have the privilege of hearing from leading experts, researchers, and clinicians who are at the forefront of developing new therapies and treatment strategies. With a combination of cutting-edge research presentations and engaging interactions, we aim to foster meaningful discussions about the most recent innovations, challenges, and breakthroughs in immunotherapy.

We are proud to present a comprehensive program featuring renowned speakers, each sharing their expertise on topics ranging from immune system modulation to the clinical applications of CAR T-cell therapy, T cell engagers, and B-cell lineage targeting in autoimmunity. These discussions will deepen our understanding and broaden the potential for more effective, personalized treatments.

Preliminary Program:

Day 1 – Thursday, September 18, 2025
14:00-15:45Session 1: Introduction to CAR-T- and T-cell engagers in autoimmunity
14:00-14:15Welcome
Dror Mevorach, Israel, Mohamad Mohty, France,  Arnon Nagler, Israel
14:15-15:00Plenary lecture: SLE pathogenesis and CAR T regulatory cell treatment
George Tsokos, USA
15:00-15:45From SLE to myasthenia gravis: What are the current bispecific/tri-specific T-cell engagers and CAR T in development for autoimmunity?
Dror Mevorach, Israel
16:00-16:30Coffee break
16:30-17:15Session 2: Resetting autoimmunity treatment
16:30-17:00Rheumatoid arthritis: From inverse pyramid through biologics to CAR T and BiTE. Historical perspective
Josef Smolen, Austria
17:00-17:30Resetting autoimmunity in immune-mediated inflammatory diseases
Gerhard Krönke, Germany
17:30-18:15Session 3: Oral Abstract Presentations
18:45WELCOME RECEPTION
CAR T- BCMA in Autoimmune Diseases Day 2 – Friday, September 19, 2025
09:00-10:30Session 4: From haemato-oncology to rheumatology
09:00-09:30CAR T-cells: From hematology to autoimmunity
Arnon Nagler, Israel
09:30-10:00Current European guidelines for HSCT and CAR T in autoimmune diseases
Raffaella Greco, Italy
10:00-10:30CAR-T- and T-cell engagers
TBA
10:30-11:00Coffee break
11:00-13:00Session 5:
11:00-11:30TBA
11:30-12:00CAR T for scleroderma? Could we cure the disease?
TBA
12:00-12:30CAR T in neurological autoimmunity
Aiden Haghikia, Germany
12:30-13:00

CAR T- BCMA in Autoimmune Diseases
Chamutal Gur, Israel

13:00-14:00Lunch
14:00-16:00Session 6: Miscellaneous cell therapies for autoimmunity

14:00-14:45

Plenary lecture: CRISPR-based T-cell editing for allogeneic CAR T
Huji Xu, China

14:45-15:15

Are cells from patients with autoimmunity suitable for CAR T generation? Limits and perspectives
Michael Aigner, Germany

15:15-15:45

NK cell therapy: from oncology to autoimmunity
TBA

15:45-16:15

Additional cell therapies and their role in autoimmunity (iPSCs, MSC, apoptotic)
TBA

16:15-16:45

Coffee break

16:45-18:15

Session 7:

16:45-17:15

Oral presentations

17:15-18:15

Poster viewing

18:15-19:00

Session 8:

18:15-19:00

Debate: Autologous or heterologous CAR T therapy for autoimmunity?
TBA
19:30FACULTY DINNER
Day 3 – Saturday, September 20, 2025
09:00-10:30Session 9: 
09:00-09:30T-cell engagers in autoimmune diseases
Ricardo Grieshaber-Bouyer, Germany
09:30-10:00CAR T safety in autoimmune diseases
Melanie Hagen, Germany
10:00-10:30Is there a cancer risk in treating patients with CAR T?
Remy Dulery, USA
10:30-11:00Coffee break
11:00-13:00Session 10:
11:00-11:30TBA
11:30-12:00Commercially conscious development of cell therapies
TBA
12:00-12:30Autoreactive B-cell depletion by CAR T-cells for ANCA vasculitis
Avery Posey, Jr., USA
12:30-13:00TBA
13:00-14:00Lunch
14:00-16:00Session 11: Near future perspectives
14:00-14:30CAR T-IL-10
Tang Li, Switzerland
14:30-15:00Increasing CAR T efficiency
Jamie Frankish, Ireland
15:00-15:30Systematic identification of targets improving T-cell therapies
Laurie Menger, France
16:00-16:30Coffee break
16:30-18:00Session 12:
16:30-17:30Debate: CAR T or BiTE for autoimmunity?
TBA
17:30Closing remarks
Dror Mevorach, Israel, Mohamad Mohty, France,  Arnon Nagler, Israel

KEY DATES

Event Start Date
18 Sep, 2025
Event Start Date
Event End Date
20 Sep, 2025
Event End Date

TARGET AUDIENCE

PhysicianEndocrinologistsScientistsStudentsDermatologistsResidentsNeurologistsNursesGastroenterologistsRheumatologistsImmunologists

SPECIALITIES

RheumatologyImmunotherapiesGastroenterologyNeurologyDermatologyEndocrinologyHaematology

SUGGESTED HOTELS

CONFERENCE VENUE

LocationLe Meridien Etoile
81 Boulevard Gouvion-Saint-Cyr,

CANCELLATION & REFUND POLICY

All cancellations must be faxed, electronically mailed or postmarked. Refund of registration fees will be as follows:

Postmarked up until June 18, 2025- 100% refund (minus € 50 handling fee and bank charges)

Postmarked from June 19, 2025- 50% refund

No refund on cancellations sent after September 1, 2025.

RELATED CONFERENCES & LIVE WEBINARS